Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Capital Expenditures (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Capital Expenditures for 15 consecutive years, with $144000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 321.54% to $144000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 48.6% year-over-year, with the annual reading at $1.2 million for FY2025, 48.6% down from the prior year.
  • Capital Expenditures for Q4 2025 was $144000.0 at Gyre Therapeutics, down from $668000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.5 million in Q2 2023, with the low at -$65000.0 in Q4 2024.
  • Average Capital Expenditures over 4 years is $962615.4, with a median of $668000.0 recorded in 2025.
  • The sharpest move saw Capital Expenditures tumbled 102.8% in 2024, then soared 321.54% in 2025.
  • Over 4 years, Capital Expenditures stood at $492000.0 in 2021, then surged by 372.36% to $2.3 million in 2023, then plummeted by 102.8% to -$65000.0 in 2024, then skyrocketed by 321.54% to $144000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $144000.0, $668000.0, and $256000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.